IL-17

Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com First In Class, TYK2 Inhibitor FDA Approved for Psoriasis 2022 New ACR Guidance…

Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…

At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as…

By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around (lots of sneaker mileage)!  And congrats to…

At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). I will be sharing the details of these studies once they are presented. There are new therapies that…